EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Heterocycles–Containing HDAC Inhibitors Active in Cancer: An Overview of the Last Fifteen Years

Alessia Raucci iD, Carola Castiello iD, Antonello Mai iD, Clemens Zwergel iD, Sergio Valente iD

ChemMedChem · 2024

DOI: 10.1002/cmdc.202400194 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemMedChem, 2024. Verfasst von Alessia Raucci und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Histone Deacetylases, Heterocyclic Compounds, Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 199 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AIRC, PRIN, Ateneo Sapienza Project 2020.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer is one of the primary causes of mortality worldwide. Despite nowadays are numerous therapeutic treatments to fight tumor progression, it is still challenging to completely overcome it. It is known that Histone Deacetylases (HDACs), epigenetic enzymes that remove acetyl groups from lysines on histone's tails, are overexpressed in various types of cancer, and their inhibition represents a valid therapeutic strategy. To date, some HDAC inhibitors have achieved FDA approval. Nevertheless, several other potential drug candidates have been developed. This review aims primarily to be comprehensive of the studies done so far regarding HDAC inhibitors bearing heterocyclic rings since their therapeutic potential is well known and has gained increasing interest in recent years. Hence, inserting heterocyclic moieties in the HDAC‐inhibiting scaffold can be a valuable strategy to provide potent and/or selective compounds. Here, in addition to summarizing the properties of novel heterocyclic HDAC inhibiting compounds, we also provide ideas for developing new, more potent, and selective compounds for treating cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone Deacetylase InhibitorsHistone DeacetylasesHeterocyclic CompoundsNeoplasmsAntineoplastic AgentsHumansMolecular StructureStructure-Activity RelationshipCell Proliferation

Stichwörter der Autor:innen

CancerEpigeneticsHDAC inhibitionHeterocycles

Substanzen

Histone Deacetylase InhibitorsHistone DeacetylasesHeterocyclic CompoundsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy.
  • Pasteur Institute, Cenci Bolognetti Foundation, Sapienza University, Piazzale Aldo Moro 5, 00185, Rome, Italy.

ORCID-Profile: Alessia Raucci, Carola Castiello, Antonello Mai, Clemens Zwergel, Sergio Valente

Förderung

  • AIRC
  • PRIN
  • Ateneo Sapienza Project 2020
  • FISR2019_00374 MeDyCa
  • FSE REACT-EU within the program PON "Research and Innovation" 2014-2020, Action IV.6 "Contratti di ricerca su te-matiche Green"
  • Italian Ministry of Health Ricerca Finalizzata
  • Kohr Aerospace

Zitieren

APA

Raucci, A., Castiello, C., Mai, A., Zwergel, C., & Valente, S. (2024). Heterocycles–Containing HDAC Inhibitors Active in Cancer: An Overview of the Last Fifteen Years. ChemMedChem. https://doi.org/10.1002/cmdc.202400194

Vancouver

Raucci A, Castiello C, Mai A, Zwergel C, Valente S. Heterocycles–Containing HDAC Inhibitors Active in Cancer: An Overview of the Last Fifteen Years. ChemMedChem. 2024. doi:10.1002/cmdc.202400194

BibTeX
@article{Raucci2024,
  author = {Raucci, Alessia and Castiello, Carola and Mai, Antonello and Zwergel, Clemens and Valente, Sergio},
  title = {Heterocycles–Containing HDAC Inhibitors Active in Cancer: An Overview of the Last Fifteen Years},
  journal = {ChemMedChem},
  year = {2024},
  doi = {10.1002/cmdc.202400194}
}
Kostenlos starten →